Allarity Therapeutics Files 2024 10-K: Net Loss of $200K

Ticker: ALLR · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1860657

Sentiment: bearish

Topics: 10-K, financials, loss, pharmaceutical

TL;DR

Allarity Therapeutics 2024 10-K: $7.3M assets, $9.8K liabilities, $200K net loss. No revenue.

AI Summary

Allarity Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported total assets of $7.3 million and total liabilities of $9,812. For the year ended December 31, 2024, the company had no revenue and incurred a net loss of $200,000. The filing also details various share and warrant information, including Series A Preferred Stock.

Why It Matters

This 10-K filing provides a comprehensive overview of Allarity Therapeutics' financial health and operational status for 2024, crucial for investors assessing the company's performance and future prospects.

Risk Assessment

Risk Level: high — The company reported no revenue and a net loss, indicating significant financial challenges and a high risk of continued operational difficulties.

Key Numbers

Key Players & Entities

FAQ

What was Allarity Therapeutics' total revenue for the fiscal year ended December 31, 2024?

Allarity Therapeutics reported $0 in revenue for the fiscal year ended December 31, 2024.

What were the total assets of Allarity Therapeutics as of December 31, 2024?

The total assets of Allarity Therapeutics as of December 31, 2024, were $7,302,797.

What was the net loss for Allarity Therapeutics for the year ended December 31, 2024?

The net loss for Allarity Therapeutics for the year ended December 31, 2024, was $200,000.

What is the company's primary industry classification?

Allarity Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].

What is the filing date of this 10-K report?

This 10-K report was filed on March 31, 2025.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding Allarity Therapeutics, Inc. (ALLR).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing